A detailed history of Barclays PLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Barclays PLC holds 155,741 shares of ALT stock, worth $1.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
155,741
Previous 155,741 -0.0%
Holding current value
$1.21 Million
Previous $956,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$5.5 - $8.1 $412,852 - $608,018
75,064 Added 93.04%
155,741 $956,000
Q2 2024

Aug 14, 2024

SELL
$5.91 - $10.23 $116,296 - $201,305
-19,678 Reduced 19.61%
80,677 $535,000
Q1 2024

May 15, 2024

BUY
$8.22 - $13.81 $229,601 - $385,740
27,932 Added 38.57%
100,355 $1.02 Million
Q4 2023

Feb 15, 2024

SELL
$2.14 - $11.62 $231,090 - $1.25 Million
-107,986 Reduced 59.86%
72,423 $814,000
Q3 2023

Nov 07, 2023

BUY
$2.4 - $3.45 $165,633 - $238,098
69,014 Added 61.95%
180,409 $470,000
Q2 2023

Aug 03, 2023

SELL
$3.45 - $5.97 $398,357 - $689,332
-115,466 Reduced 50.9%
111,395 $394,000
Q1 2023

May 04, 2023

SELL
$4.19 - $16.83 $563,052 - $2.26 Million
-134,380 Reduced 37.2%
226,861 $957,000
Q4 2022

Feb 13, 2023

BUY
$8.74 - $16.45 $1.51 Million - $2.85 Million
173,277 Added 92.19%
361,241 $5.94 Million
Q3 2022

Nov 03, 2022

SELL
$10.67 - $22.41 $9.36 Million - $19.7 Million
-877,583 Reduced 82.36%
187,964 $2.4 Million
Q2 2022

Aug 12, 2022

SELL
$3.94 - $11.77 $353,551 - $1.06 Million
-89,734 Reduced 7.77%
1,065,547 $12.5 Million
Q1 2022

May 16, 2022

BUY
$5.9 - $9.45 $355,303 - $569,088
60,221 Added 5.5%
1,155,281 $7.04 Million
Q4 2021

Feb 14, 2022

BUY
$8.69 - $12.48 $7.06 Million - $10.1 Million
812,041 Added 286.92%
1,095,060 $10 Million
Q3 2021

Nov 09, 2021

BUY
$8.43 - $16.81 $1.81 Million - $3.61 Million
215,047 Added 316.38%
283,019 $3.2 Million
Q2 2021

Aug 13, 2021

BUY
$9.85 - $16.46 $346,000 - $578,190
35,127 Added 106.95%
67,972 $670,000
Q1 2021

May 13, 2021

BUY
$12.71 - $24.31 $57,766 - $110,488
4,545 Added 16.06%
32,845 $464,000
Q4 2020

Feb 11, 2021

BUY
$7.84 - $14.22 $784 - $1,422
100 Added 0.35%
28,300 $319,000
Q3 2020

Nov 12, 2020

SELL
$9.93 - $33.26 $908,743 - $3.04 Million
-91,515 Reduced 76.44%
28,200 $372,000
Q2 2020

Aug 12, 2020

BUY
$2.9 - $10.71 $347,173 - $1.28 Million
119,715 New
119,715 $1.28 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $380M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.